Skip to main content
. Author manuscript; available in PMC: 2018 Jul 4.
Published in final edited form as: Leuk Lymphoma. 2017 Nov 8;59(7):1624–1633. doi: 10.1080/10428194.2017.1397658

Table 4.

Rates of grade ≥3 HSR across all six COG studies.

IM IV
COG regimen Dose and phase of
pegaspargase evaluated		 Number of
patients		 Grade ≥3
HSRs		 Rate
(%)		 Number of
patients		 Grade ≥3
HSRs		 Rate
(%)		 p Value
(Chi square test)
Regimen with IM then IV Dose 2 and 3 during consolidation 763a 104 13.6 397a 42 10.6 .13
Regimens with 2 doses Dose 2 during delayed Intensification 1380b 7 0.5 2851c 53 1.9 .0005
Regimens with 3+ doses Dose 2 and 3 during consolidation 3132d 442 14.1 1342e 163 12.1 .08
Regimens with 3+ doses Doses 2 and 3 during CONS or DI 4534f 459 10.1 4443g 222 5.0 <.0001
Regimens with 2 doses Doses 1 and 2 during induction and DI 5164 20 0.4 4848 70 1.4 <.0001
Regimens with 3+ doses Doses 1–5 during all phasesh 3817 462 12.1 2705 175 6.5 <.0001
All regimens Doses 1–5 during all phasesh 8981 482 5.4 7553 245 3.2 <.0001
a

AALL0434

b

AALL0331

c

AALL0932

d

AALL0232, AALL0434

e

AALL1131, AALL0434, AALL07P4

f

AALL0331, AALL0232, AALL0434

g

AALL0932, AALL1131, AALL0434, AALL07P4

h

Induction, consolidation, and delayed intensification.

CONS: consolidation; DI: delayed intensification.